Where others have failed will Atl1102 succeed ?, page-584

So..Sarepta can have US rights for $300m upfront and $1 billion in Biobucks @Uboy

Fair enough numbers. Its all for consideration within the context that Roche paid out an upfront of US$750m and US$400m in equity plus up to US$1.7B in regulatory and sales milestones plus royalties - for rights to an ineffective gene therapy outside the US. We do have to remember, however, that in Pharma Land, an anti-inflammatory is Cinderella in the kitchen looking after the chores. It would be unsurprising if you got your wish and Cinderella is off to the Royal Gene Therapy Ball. Charming.